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Abstract 
Background: Infections by both human oncoviruses, human Papillomaviruses (HPV) and Epstein–Barr virus (EBV) are 
very common in the adult human population and are associated with various malignancies. While HPV is generally 
transmitted sexually or via skin‑to‑skin contact, EBV is frequently transmitted by oral secretions, blood transfusions 
and organ transplants. This study aims to determine the prevalence and circulating genotypes of HPV and EBV in 
healthy blood donors in Qatar.
Methods: We explored the co‑prevalence of high‑risk HPVs and EBV in 378 males and only 7 females blood donors of 
different nationalities (mainly from Qatar, Egypt, Syria, Jordan, Pakistan, and India) residing in Qatar, using polymerase 
chain reaction (PCR). DNA was extracted from the buffy coat and genotyping was performed using PCR and nested‑
PCR targeting E6 and E7 as well as LMP‑1 of HPV and EBV, respectively.
Results: We found that from the total number of 385 cases of healthy blood donors studied, 54.8% and 61% of the 
samples are HPVs and EBV positive, respectively. Additionally, our data revealed that the co‑presence of both high‑risk 
HPVs and EBV is 40.4% of the total samples. More significantly, this study pointed out for the first time that the most 
frequent high‑risk HPV types in Qatar are 59 (54.8%), 31 (53.7%), 52 (49.1%), 51 (48.6%), 58 (47%) and 35 (45.5%), while 
the most commonly expressed low‑risk HPV types are 53 (50.6%), 11 (45.5), 73 (41.7%) and 6 (41.3%), with all the cases 
showing multiple HPVs infection.
Conclusion: In this study, we demonstrated for the first time that HPV and EBV are commonly co‑present in healthy 
blood donors in Qatar. On the other hand, it is important to highlight that these oncoviruses can also be co‑present in 
several types of human cancers where they can cooperate in the initiation and/or progression of these cancers. There‑
fore, more studies regarding the co‑presence of these oncoviruses and their interaction are necessary to understand 
their cooperative role in human diseases.
Keywords: HPV, EBV, Healthy blood donors, Qatar
© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and 
the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material 
in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material 
is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the 
permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco 
mmons .org/licen ses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/publi cdoma in/
zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Human Papillomaviruses (HPVs) and Epstein–Barr 
virus (EBV) are human oncoviruses that can co-exist 
together. HPVs are small, double-stranded DNA viruses 
which tend to infect cutaneous and mucosal epithe-
lial tissues of the ano-genital tract [1]. HPVs are cat-
egorized into high-risk or low-risk. Infections due to 
low-risk HPV subtypes (mostly, HPVs-6 and 11) are 
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commonly self-limiting diseases resulting in the prolif-
eration of epithelial cells that manifests as skin or geni-
tal warts or skin papilloma [2, 3]. On the other hand, 
high-risk HPV subtypes (16, 18, 31, 33, 35, 39, 45, 51, 
52, 56, 58, 59 and 68) are associated with the develop-
ment of several types of human carcinomas [2, 3]. In 
particular, cancers developing in the cervix, ano-genital 
tract as well as oropharynx region are frequently cor-
related with chronic high-risk HPV infection [4, 5]. 
While HPV infections are eradicated by the immune 
system, persistent chronic infections associated with 
high expression levels of E6/E7 (viral oncogenes) as 
well as accretion of cellular mutations may cause altera-
tions in TP53 and RB expressions, which are known as 
tumor suppressor genes [6]. Additionally, it has been 
reported that high-risk HPVs (E5 and E6/E7) oncopro-
teins, can enhance cancer progression of human carci-
nomas via the initiation of the epithelial-mesenchymal 
transition (EMT) which is a hallmark of cancer metas-
tasis [7–9]. On the other hand, it is important to note 
that HPVs transmissions may be enhanced by the pres-
ence of rough or macerated epithelial surfaces [10]. 
Several studies have demonstrated that HPV DNA can 
be present in circulating blood, including peripheral 
blood mononuclear cells (PBMCs), sera, plasma, and 
arterial cord blood [11–15].
Human herpesvirus 4, commonly known as Epstein–
Barr virus is a DNA lymphotropic herpesvirus that 
causes infectious mononucleosis [16]. EBV comprises of 
a 172 kbp double-stranded DNA genome encoding for 
around 85 genes [17, 18]. There are two EBV genotypes, 
Type 1 and Type 2 [19]. Various viral oncogenes such as 
EBV-encoded nuclear antigens (EBNA [1–3]) and the 
latent membrane proteins (LMP [1, 2]) are encoded by 
the EBV [20]. LMP-1 is a 356-amino acid protein [21] and 
is involved in signal transduction and cell survival [18]. 
Since LMP1 regulates cell growth, protects cells from 
apoptosis, promotes cell motility, and angiogenesis, it is 
considered as the principal EBV-encoded oncogenic pro-
tein [22]. LMP-1 variants are divided into 7 core groups 
including B95-8, Alaskan, China 1, China 2, Med+ , 
Med− , and NC [18, 23, 24]. LMP1 can stimulate sev-
eral signaling pathways especially those involved in the 
induction of EMT such as NF-κB, PI3K/Akt, and MAPK 
[7]. The other EBV onco-protein, LMP2A [25] regulates 
the invasive/migratory ability and stimulates changes in 
EMT-like cellular biomarkers [26] by targeting the rapa-
mycin (mTOR) pathway [22]. On the other hand, EBNA1, 
a key product of EBV, is involved in the replication and 
maintenance of the EBV genome [27] and regulates EMT 
through the de-regulation of SLUG, SNAIL, TCF8/ZEB1, 
vimentin, occludins-1, as well as E-cadherin [9]. EBV is 
primarily transmitted through the oral route; however, 
blood transfusions and organ transplantations are also 
other possible transmission routes of EBV [28–30].
Several recent studies have demonstrated that the co-
presence of high-risk HPVs and EBV mRNA in various 
human malignancies including cervical, breast and oral 
cancers, indicating their active role in cancer initiation 
and metastatic progression via the acceleration of EMT 
through numerous common signaling pathways [11, 31].
In light of these findings, the objective of this study 
is to explore the presence of HPV and EBV DNA in the 
blood of healthy individuals in the Middle East region, 
more specifically in Qatar.
Materials and methods
Sample collection and ethical approval
A total of 385 whole blood samples (139 from Qataris 
and 246 from other nationalities) were collected in EDTA 
tubes from healthy donors at the Blood Donor Unit of 
Hamad Medical Corporation (HMC) over a period of 1 
year (September 2014–September 2015) as previously 
described [32]. Blood samples were handled and stored 
following standard safety procedures and guidelines. This 
study was approved by HMC-Institutional Review Board 
(HMC-IRB #14292/14) and Qatar University IRB (QU-
IRB 518-EA/15) [32].
DNA extraction
DNA was extracted from PMNCs (buffy coat samples) 
suspended in 200  μl of PBS using Qiagen kit following 
the manufacturer’s instructions (Qiagen, Germany) as 
previously described [32]. The concentration and purity 
of all extracted DNA samples were measured using 
NanoQuant microplate reader (Tecan, Switzerland). 
Extracted DNA samples were then stored at − 20 °C for 
further testing.
HPV and EBV detection
Twenty-five nm of purified genomic DNA (Qiagen, Ger-
many), from each sample, was analyzed for HPV and 
EBV by polymerase chain reaction (PCR) using specific 
primers as follows:
The E6/E7 and L1 region of HPV types; GP5/6, 6, 11, 
16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 
73 and 82 were amplified (Table  1), while, primers for 
GAPDH gene (Forward Primer: 5′-GAA GGC -CAT GCC 
AGT GAG CT-3′ and Reverse Primer: 5′-CCG GGA AAC 
TGT GGC GTG AT-3′) were used as an internal control.
On the other hand, a nested PCR of the LMP-1 gene 
was done as previously described [32]. In the first round 
of amplification, primers A1 (5′-AGT CAT AGT AGC 
TTA GCT GAA-3′) and A2 (5′-CCA TGG ACA ACG ACA 
CAG T -3′) amplified a fragment of 602  bp covering 
the C-terminus of LMP-1 gene. In the second round of 
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amplification, primers B1 (5′-AGT CAT AGT AGC TTA 
GCT GAA-3′) and B2 (5′-CAG TGA TGA ACA CCA CCA 
CG-3′) amplified a 587 bp fragment. The annealing tem-
perature for the LMP-1 gene was 53 °C.
Amplification conditions included an initial heat acti-
vation step of 15 min at 95  °C; 40 cycles of PCR ampli-
fications at 95 °C for 30 s, annealing (Table 1) for 30 s in 
addition to 1 min at 72  °C; and a final extension step of 
72  °C for 10 min. Analysis was performed as previously 
described by our group [33, 34]. Amplified products 
were analyzed by 1.5% agarose gel electrophoresis and 
visualized using iBrightCL1000 Imaging System (Ther-
moFisher). In each experiment, negative control (MDA-
MB-453 cell line [35] and sterile water instead of DNA) 
and positive control (such as Hela cell line for L1 region 
[36] and normal oral epithelial (NOE) cell line trans-
fected with E6/E7 of HPV type 16 for E6/E7 region [37]) 
were used.
Statistical analysis
To determine the relation significance between 
variable ratios, Chi square test was used. Results 
with  p-value < 0.05 were considered statistically sig-
nificant. The analysis was performed using Statistical 
Package for Social Sciences  (SPSS) version 25 software 
(IBM SPSS).
Results
Demographic data and main findings
Of the total 385 blood samples analyzed in the present 
study, 378 samples (98.1%) were from males and seven 
samples (1.8%) from females. The majority of the sam-
ples were obtained from non-Qatari residents (66.2%), 
and the rest were from Qatari individuals (33.7%). The 
age of participants ranged between 19 and 68  years, 
(37.12 ± 9.3 years). Based on the study conducted previ-
ously [32], of the total 385 blood samples, 235 (61%) were 
positive for EBV; Table  2 summarizes the demographic 
data of the studied population. The present investiga-
tion revealed that 60.5% and 47.3% are positive for low-
risk and high-risk HPVs, respectively. In parallel, we were 
able to show that EBV and HPVs are co-present in 40.4% 
and 50.6% for high-risk and low-risk HPVs, respectively.
Prevalence of low‑risk HPVs in healthy blood donors 
in Qatar
We herein explored the presence of low-risk HPVs in 
healthy blood donors from Qatar, in both EBV positive 
and negative groups. Table 3 summarizes the prevalence 
Table 1 The specific primer sets for HPV used for polymerase chain reaction (PCR) amplification
HPV type Forward primer (5′‑3′) Reverse primer (5′‑3′) Ta (°C)
E6/E7 region
 16 ATG CAT GGA GAT ACA CCT ACA TTG CAT GTT TCT GAG AAC AGA TGG GGC ACA C 61
 18 GCT TTG AGG ATC CAA CAC GG TGC AGC ACG AAT GGC ACT GG 61
 31 GGG CTC ATT TGG AAT CGT GTG AAC CAT TGC ATC CCG TCC CC 61
 33 TGA GGA TGA AGG CTT GGA CC TGA CAC ATA AAC GAA CTG TG 61
 35 CTA TTG ACG GTC CAGCT TAC ACA CAG ACG TAG TGT CG 61
 45 CCC ACG CGA ACC ACAG TCT AAG GTC CTC TGC CGA GC 46.3
 51 TAC GTG TTA CAG AAT TGA AG AAC CAG GCT TAG TTC GCC CATT 46.3
 52 GCA GAA CAA GCC ACA AGC AA TAG AGT ACG AAG GTC CGT CG 60
 58 CGA GGA TGA AAT AGG CTT GG ACA CAA ACG AAC CGT GGT GC 40.5
L1 region
 GP5/GP6 TTT GTT ACT GTG GTA GAT ACTAC GAA AAA TAA ACT GTA AAT CAT ATT 50.5
 6 TGT CCC ATC TGC GCA CCG AAGAC CGT ACA CTG TTT GTG GGC GCTTC 42.5
 11 AGT TCC GTA GAT GCC AAG GGCA TGC CTC AGG TGA GGC CCA ATGC 42.5
 26 TGG TAT ACA ACG AGT GTC AGC TCC GGG GCA ATG ATG GCC ATG TCG 40.5
 39 TGT GCA GTA CCA GTG ACG GATCG ATT TTT GGC GTT GTG ACT CTGTG 40.5
 53 TTG TTC AGT GTA CGG GGC TAGC GTG ACG CCA TTG CAG TTA TCG CCT 43.3
 56 CTG GGC ACT AGG TCA AAG CCT GCT CAA CCA CGC GTA AAA GCA CTCAT 53.8
 59 AGA CAC CGT TAC ATG AGC TGCT TCA TTC TCG GAG TCG GAG TCAG 43.3
 66 TGC GGT AGT ATC CTT GGG CAGTG TAC AAT AAG GGC CAC ACG CCAA 46.3
 68 GTC AAA AAG ACG CCC CTG CAC CTA CAC ACC TTA GGG TAG GGC TACAA 48.8
 73 GGG GTG GGC AAA GGT AGG TAGC ACA ATC CAG GGG CCT CTG GTC CGA 48.8
 82 TGT CCG TGG ACA CCT GCG ACCA GTA GTT AAA GGT GAT GTG GCA ACC 48.8
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of low-risk HPVs in healthy blood donors, based on our 
PCR analysis using specific primers for LMP1 as well 
as E6/E7 genes of EBV and HPVs, respectively (Materi-
als and Methods Section). It is worth noting that using 
GP5+/6+ primer set is a highly sensitive specific method 
for HPV DNA detection [38] as it targets L1 conserved 
regions of the viral genome; thus, allowing detection of 
a comprehensive variety of HPV genotypes [39, 40]. We 
found that GP5/GP6 was positive for more than 60% of 
the samples and hence, further analysis was performed to 
determine HPV subtypes.
Analysis revealed that of the total 385 samples, 235 
were positive and 150 were negative for EBV. On the 
other hand, 233 of the total samples (60.5%) were posi-
tive for low-risk HPVs, and all of the positive cases 
were infected with more than one type of low-risk HPV 
(Fig.  1). This number represents 50.6% of the 235 EBV-
positive samples, and 76% of the 150 EBV-negative sam-
ples. Moreover, data revealed that the most prevalent 
low risk HPV types were HPV-6 and 73 (both at 54.8%), 
followed closely by HPV-11 (52.5%) and HPV-53 (51.9%) 
(Table 3).
Prevalence of high‑risk HPVs in healthy blood donors 
in Qatar
We further investigated the co-presence of high-risk 
HPVs and EBV in our samples by PCR using specific 
primers for E6/E7 as well as LMP1 genes of HPVs and 
EBV, respectively (Table 4). Analysis revealed that 182 of 
Table 2 Demographic data of  the  subjects positive (235) 
and negative (150) for EBV
EBV positive (235) EBV negative (150)
Category Total no. (%) Total no. (%)
Nationality & gender
 Qatari 102 (43.4%) 28 (18.66%)
 Male 101 27
 Female 1 1
 Non‑Qatari 133 (56.5%) 122 (81.33%)
 Male 131 119
 Female 2 3
Age group
 20–39 52 (22.12%) 46 (30.66%)
 30–39 95 (40.4%) 63 (42%)
 40–49 60 (25.5%) 34 (22.66%)
 50–59 28 (11.91%) 7 (4.66%)
Table 3 Prevalence of  low-risk HPVs in  healthy blood 
donors from Qatar
Samples No. of cases Low‑risk HPV types (%)
6 11 53 73
EBV (+) 235 41.3 45.5 50.6 41.7
EBV (−) 150 76 63.3 54 75.3
Total 385 54.8 52.5 51.9 54.8
Fig. 1 Representative PCR reactions for low‑risk HPV‑subtypes in 15 different EBV‑positive and EBV‑negative healthy blood donors
Table 4 Prevalence of high-risk HPVs in samples from healthy blood donors in Qatar
Samples No. of cases High‑risk HPV types (%)
16 18 26 31 33 35 39 45 51 52 56 58 59 66 68 82
EBV (+) 235 35.7 34.5 32.8 39.6 4.6 35.3 32.8 30.6 36.2 37.9 27.7 37.4 40.4 29.4 25.5 20.8
EBV (−) 150 41.3 38.6 60 76 0 61.3 62 56.6 68 66.7 22.6 62 77.3 39.3 71.3 11.3
Total 385 37.9 36.1 43.4 53.8 2.8 45.4 44.2 40.7 48.6 49.1 25.7 47 54.8 33.3 43.3 17.1
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the total number of samples were positive for high-risk 
HPVs (47.3%), representing 40.4% of the 235 EBV-posi-
tive and 58% of the 150 EBV-negative samples. Again, all 
cases were infected with more than one high-risk HPV 
type (Fig. 2). Moreover, data revealed that the most prev-
alent high-risk HPV types in EBV-positive donors were 
HPV-59 (54.8%), HPV-31 (53.8%), HPV-52 (49.1%), HPV-
51 (48.6%), HPV-58 (47%), HPV-35 (45.4%), HPV-26 
(43.4%), HPV-16 (37.9%) and HPV-18 (36.1%).
Demographic association of HPV‑Subtypes and EBV 
in Healthy Donors in Qatar
A demographic analysis of the samples from healthy 
donors by classifying them into Qataris and Non-Qataris 
showed that, in EBV-negative samples, HPV type 35 
is the only highly prevalent subtype in both popula-
tions (65.4% and 84%, respectively, p = 0.029). However, 
in EBV-positive samples, as shown in Table 5, the most 
prevalent HPV-subtypes include HPV types 52, 56, 66 
and 68 (p = 0.02, p = 0.03, p = 0.03, p = 0.02, respectively).
Discussion
Viral infections are the most common etiologic 
causes of infection-related cancer agents (~ 15%) 
[41, 42]. Although these infections predominantly 
Fig. 2 Representative PCR reactions for high‑risk HPV‑subtypes in 15 different EBV‑positive and EBV‑negative samples of healthy blood donors
Table 5 Association of  HPV subtypes in  235 EBV-positive 
samples from Qatari vs non-Qatari healthy blood donors
QATARIS v/s NON‑QATARIS
Samples HPV‑subtypes (%)
52 56 66 68
Qataris (102) 47 37.2 39.2 19.6
Non‑Qataris (133) 30.8 24.8 26.3 32.3
p‑value 0.022* 0.034* 0.0355* 0.029*
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affect developing countries, their frequency cannot 
be ignored in developed countries [43, 44]. In 38% of 
virus-related cancers, there is co-presence of HPVs 
along with EBV [42]. However, these cancers develop 
after a relatively long latent period (15–40 years) [45]. 
Viral infections within cells are not limited and their 
combined oncogenic effects can lead to the onset and/
or progression of cancer disease [42, 46].
In the present study, we investigated the co-presence 
of both low- and high-risk HPVs and EBV in the blood 
of healthy individuals from the middle east region, 
more specifically in Qatar. Several previous studies 
have already shown the occurrence of HPVs in subjects 
with unidentified HPV-related disease or cancer; viral 
DNA/RNA being identified in several tissues including 
sperm cells [47, 48], placental tissue [49, 50] as well as 
peripheral blood cells [51, 52]; indicating that HPV can 
disseminate through the bloodstream [13, 47].
Additionally, based on few studies, HPV DNA was 
shown to circulate in the bloodstream during ephem-
eral asymptomatic infections [53–55]; however, it 
was indicated that detection of HPV DNA in blood 
samples is a useful and potential biomarker of severe 
HPV-related diseases including cancer. Furthermore, 
studies have detected HPVs in blood samples of both 
males and females with non-cancer related HPV uro-
genital infections. While an earlier study in asympto-
matic women with urogenital infections reported HPV 
positivity in peripheral blood cells [52], another study 
on male patients’ blood showed HPV DNA detec-
tion in semen infection [47]. In the present study, we 
revealed that the presence of both low-risk and high-
risk HPVs is ~ 60.5% and 47.3% in healthy blood donors 
in a diverse population group from Qatar, respectively. 
Similar to our study, a study among healthy Austral-
ian male donors conducted by Chen et al. revealed the 
prevalence of 8.3% for HPV infection [51]. Metagenom-
ics analysis using whole-genome shotgun sequencing in 
748 samples collected from a cohort of 103 healthy 
North American human subjects was conducted by the 
NIH Human Microbiome Project. From each subject, 
four organs (skin, vagina, mouth, and gut) were used 
for sample collection. This study in healthy humans, 
who did not display classical HPV-associated diseases, 
revealed the overall HPV prevalence of 68.9%; the high-
est being present in the skin (61.3%), followed by the 
vagina (41.5%), mouth (30%), and gut (17.3%). The co-
existence of multiple HPV types was found in 48.1% 
of HPV-positive samples [56]. This high prevalence of 
HPV and coexistence of HPV subtypes in the blood of 
healthy subjects could be attributed to its presence at 
multiple body sites, as reported previously [56].
Our study has some limitations: Given that it included a 
very low number of female participants due to socio-cul-
tural factors and religious/fatalistic barriers, in addition 
to low levels of hemoglobin in women which is reported 
as a cause of donor loss [57–60], it is essential to per-
form other studies of a larger number of cases that may 
ensure a higher female participation in Qatar in order to 
clarify gender variations in HPV and EBV distribution in 
this population. Such studies are essential for the region 
in order to allow for the selection of the right HPV and 
EBV vaccines as a necessary preventive tool against sev-
eral serious diseases associated with these oncoviruses, 
including cancer. In addition, we cannot anticipate the 
real clinical impact of the observed frequencies of HPV 
and EBV in the population of Qatar. However, our group 
is currently exploring the co-presence of HPVs and EBV 
in different types of cancers in Qatar including breast, 
cervical as well as colorectal; analysis in breast and cervi-
cal cancers can aid in providing clear data about role of 
high-risk HPVs and EBV in female cases.
On the other hand, our present study showed for the 
first time the co-presence of high and low-risk HPVs 
with EBV in 40.4% and 50.6% of the examined samples, 
respectively. More specifically, in EBV-negative samples, 
approximately more than half of the Qataris were posi-
tive for low-risk skin HPV-types HPV-6, 11, 53 and 73 
(Table 3) that are frequently expressed in asymptomatic 
infections of normal, healthy skin [61, 62]. The rest were 
high-risk HPV types that are linked with cancer devel-
opment. Moreover, the most significantly expressed 
high-risk HPV subtypes in Qatari healthy donors are 
in line with previous studies on HPV prevalence in the 
Middle East [63–65], thus they included HPV-52, 56, 66 
and 68 (p = 0.02, p = 0.03, p = 0.03, p = 0.02, respectively, 
Table  4). Although the percentage of Qatari healthy 
donors in this study is small, this HPV DNA prevalence 
in healthy males’ merits further investigation.
Conclusions
Our study provides evidence that HPV and EBV can 
be detected and quantified in blood samples of healthy 
blood donors without any obvious HPV infection, sug-
gesting potential viral persistence at different anatomi-
cal sites. This random distribution of HPV subtypes 
along with EBV, suggests potential facilitative or com-
petitive interactions among these onco-viruses, which 
has been recently reported by several studies [31, 34, 
46, 66]. Since these oncoviruses can be found in vari-
ous cancers; our group has previously demonstrated 
that E6/E7 of high-risk HPVs can convert non-invasive 
cancer cells to invasive phenotypes [22]. Addition-
ally, HPVs genotyping can help select the most rele-
vant HPV vaccine to prevent HPV-associated cancers. 
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However, further studies are required to assess the role 
of HPV DNA detection in the bloodstream of people 
with asymptomatic infection to elucidate the underly-
ing mechanisms of the co-presence of HPVs and EBV 
in healthy donors; especially since vaccines for these 
onco-viruses are available or are currently under clini-
cal trial [67–69]. This is a vital step as vaccinating indi-
viduals can aid in lowering the risk of viral transmission 
in the common population and ultimately prevent the 
onset of HPVs- and EBV-related diseases, including 
cancer. The co-prevalence of HPVs and EBV among 
healthy blood donors should draw the attention of cli-
nicians, researchers and healthcare workers in Qatar, 
which could aid in promoting safety practices in health 
care centers, especially in blood banks and organ trans-
plant centers.
In conclusion, our study revealed that both low-risk 
and high-risk HPVs are frequently co-present with 
EBV among healthy blood donors in the heterogeneous 
population of Qatar. Further observational and clinical 
studies are required to assess the full relevance of the 
obtained data.
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